Advancing Computational Toxicology to Better Predict Safety for Complex Modalities Including Larger Molecules
- Benchmark evolving in silico approaches that bridge data gaps for large molecules and gene therapy where limited clinical and preclinical datasets hinder model accuracy and validation
- Learn strategies to integrate computational insights with in vitro and in vivo evidence to strengthen species relevance decisions mitigate sampling bias and improve translatability across platforms
- Explore how to evaluate combination therapy safety by modelling target pathway interactions dose considerations and additive or offsetting toxicity risks to support more confident regulatory acceptance